Clinical Laserthermia Systems AB publishes interim report January – September 2022
Summary of the interim report (relates to the Group) Nine months (01/01/2022–09/30/2022) · Net sales totaled SEK 1,973,000 (SEK 901,000). · Profit/loss after financial items totaled SEK -62,192,000 (SEK -44,221,000). · Basic and diluted earnings per share totaled SEK -0.90 (SEK -1.25). · The equity ratio at September 30, 2022, was 34% (50%). Third quarter (07/01/2022–09/30/2022) · Net sales totaled SEK 884,000 (SEK 7,000). · Profit/loss after financial items amounted to SEK -30,374,000 (SEK -11,872,000). · Basic and diluted earnings per share totaled